A Phase 3 interventional study of insulin degludec/liraglutide and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 88 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 49th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 420 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 124th largest by enrollment of the 428 interventional ones that give a count, is one of 20 that started in 2016, is one of 187 in phase 3, and was the 415th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 420 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Male or female, age at least 18 years at the time of signing - Subjects diagnosed (clinically) with type 2 diabetes mellitus - 7.0-11.0% [53-97 mmol/mol] (both inclusive) by central laboratory analysis - (BMI) equal to or above 20 kg/m\^2 and below 40 kg/m\^2 - Insulin naïve subjects; however short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as well as prior insulin treatment for gestational diabetes - A stable daily dose for at least 90 days prior to the day of screening of any SGLT2i in monotherapy or in combination with metformin ± DPP4i ± pioglitazone. Use of pioglitazone is not allowed in subjects treated with dapagliflozin Exclusion Criteria: - Receipt of any medicinal product within 90 days prior to screening - Use of any OADs (other than SGLT2i in monotherapy or in combination with metformin or DPP4i or pioglitazone as described in the inclusion criteria) within 90 days prior to the day of screening - Use of glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., exenatide or liraglutide) within 90 days prior to the day of screening - Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent severe metabolic dysregulation (e.g., diabetes ketoacidosis) in the previous 90 days prior to the day of the screening - Subjects presently classified as being in (New York Heart Association) Class III or IV1 - Renal impairment estimated 60 mL/min/1.73 m2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) - Impaired liver function, defined as (alanine aminotransferase) equal to or above 2.5 times upper normal limit at screening - Known or suspected to trial product(s) or related products
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/liraglutide
Drug: insulin glargine
Drug pages: Insulin degludec · Liraglutide
IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
IGlar will be given subcutaneously ( s.c., under the skin) once daily.
Change in HbA1c (Glycosylated Haemoglobin)
The mean change from baseline (week 0) in HbA1c values evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: Week 0, Week 26
Change in Body Weight
The mean change from baseline (week 0) in body weight evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: Week 0, Week 26
Number of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe (subjects who were not able to self-treat) and/or BG confirmed by a plasma glucose values \<3.1 mmol/L (56 mg/dL) with accompanied symptoms consistent with hypoglycaemia.
Time frame: Week 0-26
Insulin Dose, Total Daily Dose (U)
Actual daily total insulin dose (Units) was evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Change in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG was evaluated after 26 weeks of randomised treatment.
Time frame: Week 0, Week 26
Number of Treatment-emergent Adverse Events
Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 26. TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
Time frame: Week 0-26
Responder (Yes/No) for HbA1c Below 7.0%
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Weight Gain
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without weight gain after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5%
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Weight Gain
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% without weight gain after 26 weeks of randomised treatment. The results are based on retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
Time frame: After 26 weeks
Change From Baseline After 26 Weeks in Waist Circumference
Mean change from baseline in waist circumference after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Fasting Lipid Profile: Cholesterol
The values of total cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Fasting Lipid Profile: Low-density Lipoprotein Cholesterol (LDL Cholesterol)
The values of LDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Fasting Lipid Profile: High-density Lipoprotein Cholesterol (HDL Cholesterol)
The values of HDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Fasting Lipid Profile: Very-low-density Lipoprotein Cholesterol (VLDL Cholesterol)
The values of VLDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Fasting Lipid Profile: Triglycerides
The values of triglycerides from fasting lipid profile after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Fasting Lipid Profile: Free Fatty Acids
The values of free fatty acids from fasting lipid profile after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in the 9-point Self-measured Plasma Glucose (SMPG) Profile
Change in 9-point SMPG profile was evaluated after 26 weeks of randomised treatment. SMPG measurements at baseline and week 26 are presented here at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.
Time frame: After 26 weeks
Change From Baseline in Self-measured Plasma Glucose (SMPG) 9-point Profile: Mean of the 9-point Profile
Change in mean of the 9-point profile SMPG was evaluated after 26 weeks of randomised treatment. 9-point profile SMPG was measured at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.
Time frame: After 26 weeks
Change From Baseline in SMPG 9-point Profile: Prandial Plasma Glucose Increments (From Before Meal to 90 Min After Breakfast, Lunch and Dinner). The Mean Increment Over All Meals Will be Derived as the Mean of All Available Meal Increments
Mean prandial plasma glucose increments for each meal (from before meal to 90 min after breakfast, lunch and dinner) was evaluated after 26 weeks of randomised treatment. The mean increment over all meals was derived as the mean of all available meal increments are presented here.
Time frame: After 26 weeks
Change From Baseline in Systolic Blood Pressure
Change from baseline (week 0) in systolic blood pressure (BP) was evaluated after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Diastolic Blood Pressure
Change from baseline (week 0) in diastolic blood pressure was evaluated after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks
Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes (00:01-05:59 - inclusive) during 26 weeks of randomised treatment.
Time frame: Week 0-26
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition During 26 Weeks
American Diabetes Association (ADA) classification of hypoglycaemic episodes: 1)Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2) Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3) Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4) Probable symptomatic: No measurement with symptoms. 5) Pseudo: PG \>3.9 mmol/L with symptoms. 6) Unclassifiable.
Time frame: Week 0-26
Change From Baseline in Clinical Evaluation After 26 Weeks: Electrocardiogram (ECG)
Reported results are ECG findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.
Time frame: After 26 weeks
Change From Baseline in Clinical Evaluation After 26 Weeks: Eye Examination: Fundoscopy/Fundus Photography
Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.
Time frame: After 26 weeks
Change From Baseline in Clinical Evaluation After 26 Weeks: Pulse Rate
Change from baseline (week 0) in pulse rate was evaluated after 26 weeks of randomised treatment.
Time frame: After 26 weeks
Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Medical Outcomes Study 36-item Short Form (SF-36v2)
The Short Form (SF)-36v2™ patient reported outcomes (PRO) questionnaire was used to assess the subject's overall health related quality of life (HRQoL). PRO questionnaire (SF-36v2™) measured the HRQoL which contains 36 items covering 8 domains of physical and mental health status. The raw scale scores from the SF-36 were transformed to a 0-100 scale scores (where higher scores indicated a better health status) which is further converted to norm-based scores using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 2009 reference population . The total/overall (SF-36v2™) scores for physical and mental health from baseline to week 26 are presented here.
Time frame: After 26 weeks
Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D)
The patient reported outcomes are calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D domain scores and the total scores are later transformed to a 0-100 scale for analysis. Summary scores from baseline and week 26 for total/overall scores are presented here.
Time frame: After 26 weeks
The trial was conducted at 74 sites in 11 countries as follows: Argentina (3), Canada (5), Finland (6), Hungary (5), India (8), Russian Federation (7), Slovakia (5), Slovenia (4), Spain (6), Switzerland (5) and United States (20).
| Milestone | IDegLira | IGlar |
|---|---|---|
| Started | 210 | 210 |
| Exposed | 209 | 210 |
| Completed | 200 | 206 |
| Not completed | 10 | 4 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Withdrawal by subject | 5 | 1 |
| Withdrew: Unclassified | 1 | 1 |
| Withdrew: Missing | 0 | 1 |
The mean change from baseline (week 0) in HbA1c values evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Percentage of glycosylated haemoglobin | IDegLira | IGlar |
|---|---|---|
| HbA1c (%) at baseline | 8.20 ± 0.93 | 8.36 ± 1.08 |
| HbA1c (%) change from baseline to week 26 | -1.94 ± 0.95 | -1.68 ± 1.05 |
The mean change from baseline (week 0) in body weight evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| kg | IDegLira | IGlar |
|---|---|---|
| Body weight (kg) at baseline | 89.3 ± 17.6 | 87.2 ± 17.2 |
| Body weight (kg) change from baseline to week 26 | -0.0 ± 3.8 | 2.0 ± 3.9 |
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe (subjects who were not able to self-treat) and/or BG confirmed by a plasma glucose values \<3.1 mmol/L (56 mg/dL) with accompanied symptoms consistent with hypoglycaemia.
| Number of episodes | IDegLira | IGlar |
|---|---|---|
| Number of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes | 38 | 95 |
Actual daily total insulin dose (Units) was evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Units (U) | IDegLira | IGlar |
|---|---|---|
| Insulin Dose, Total Daily Dose (U) | 36.2 ± 13.4 | 53.5 ± 26.1 |
Change from baseline (week 0) in FPG was evaluated after 26 weeks of randomised treatment.
| mmol/ L | IDegLira | IGlar |
|---|---|---|
| FPG (mmol/L) at baseline | 9.51 ± 2.69 | 9.57 ± 2.40 |
| FPG (mmol/L) change from baseline to week 26 | -3.72 ± 2.89 | -3.50 ± 2.43 |
Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 26. TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
| Number of events | IDegLira | IGlar |
|---|---|---|
| Number of Treatment-emergent Adverse Events | 450 | 386 |
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Participants | IDegLira | IGlar |
|---|---|---|
| Yes | 167 | 144 |
| No | 30 | 58 |
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without weight gain after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Participants | IDegLira | IGlar |
|---|---|---|
| Yes | 91 | 38 |
| No | 106 | 164 |
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Participants | IDegLira | IGlar |
|---|---|---|
| Yes | 156 | 114 |
| No | 41 | 88 |
The proportion of subjects achieving pre-defined HbA1c targets \<7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Participants | IDegLira | IGlar |
|---|---|---|
| Yes | 83 | 34 |
| No | 114 | 168 |
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Participants | IDegLira | IGlar |
|---|---|---|
| Yes | 147 | 100 |
| No | 50 | 102 |
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% without weight gain after 26 weeks of randomised treatment. The results are based on retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Participants | IDegLira | IGlar |
|---|---|---|
| Yes | 84 | 26 |
| No | 113 | 176 |
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Particpants | IDegLira | IGlar |
|---|---|---|
| Yes | 137 | 79 |
| No | 60 | 123 |
The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.
| Partcipants | IDegLira | IGlar |
|---|---|---|
| Yes | 77 | 24 |
| No | 120 | 178 |
Mean change from baseline in waist circumference after 26 weeks of randomised treatment.
| cm | IDegLira | IGlar |
|---|---|---|
| Waist circum. (cm) at baseline | 105.9 ± 12.7 | 104.7 ± 11.3 |
| Waist circum. (cm) change from baseline to week 26 | -0.6 ± 4.6 | 0.7 ± 3.9 |
The values of total cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| Total cholesterol (mmol/L) at baseline | 4.42 (2.02 to 10.62) | 4.45 (2.12 to 11.37) |
| Total cholesterol (mmol/L) at week 26 | 4.27 (2.12 to 9.87) | 4.27 (1.84 to 9.40) |
The values of LDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| LDL cholesterol (mmol/L) at baseline | 2.28 (0.26 to 7.10) | 2.28 (0.10 to 6.73) |
| LDL cholesterol (mmol/L) at week 26 | 2.20 (0.57 to 6.42) | 2.31 (0.62 to 5.34) |
The values of HDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| HDL cholesterol (mmol/L) at baseline | 1.14 (0.57 to 2.69) | 1.14 (0.31 to 2.59) |
| HDL cholesterol (mmol/L) at week 26 | 1.17 (0.57 to 2.72) | 1.17 (0.36 to 2.49) |
The values of VLDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| VLDL cholesterol (mmol/L) at baseline | 0.75 (0.18 to 8.60) | 0.80 (0.21 to 8.13) |
| VLDL cholesterol (mmol/L) at week 26 | 0.70 (0.21 to 5.75) | 0.67 (0.21 to 3.32) |
The values of triglycerides from fasting lipid profile after 26 weeks of randomised treatment.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| Triglycerides (mmol/L) at baseline | 1.67 (0.38 to 23.60) | 1.73 (0.43 to 27.80) |
| Triglycerides (mmol/L) at week 26 | 1.55 (0.46 to 17.03) | 1.47 (0.47 to 8.81) |
The values of free fatty acids from fasting lipid profile after 26 weeks of randomised treatment.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| Free fatty acids (mmol/L) at baseline | 0.58 (0.08 to 1.44) | 0.61 (0.06 to 1.73) |
| Free fatty acids (mmol/L) at week 26 | 0.38 (0.10 to 0.92) | 0.42 (0.02 to 1.30) |
Change in 9-point SMPG profile was evaluated after 26 weeks of randomised treatment. SMPG measurements at baseline and week 26 are presented here at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| Before breakfast - Baseline | 9.01 ± 2.18 | 9.00 ± 1.91 |
| Ninety (90) minutes after breakfast - Baseline | 11.79 ± 3.09 | 11.77 ± 2.99 |
| Before lunch - Baseline | 8.93 ± 2.80 | 9.20 ± 2.95 |
| Ninety (90) minutes after lunch - Baseline | 11.24 ± 3.26 | 11.22 ± 3.06 |
| Before dinner - Baseline | 9.33 ± 2.70 | 9.36 ± 2.89 |
| Ninety (90) minutes after dinner - Baseline | 11.40 ± 3.04 | 11.40 ± 2.99 |
| At bedtime - Baseline | 10.38 ± 3.16 | 10.71 ± 3.13 |
| At 4.00 AM - Baseline | 8.80 ± 2.41 | 9.00 ± 2.50 |
| Before breakfast the following day - Baseline | 8.60 ± 2.02 | 8.81 ± 1.92 |
| Before breakfast - Week 26 | 5.40 ± 1.24 | 5.39 ± 1.21 |
| Ninety (90) minutes after breakfast - Week 26 | 7.20 ± 1.86 | 8.35 ± 2.40 |
| Before lunch - Week 26 | 5.83 ± 1.36 | 6.35 ± 1.88 |
| Ninety (90) minutes after lunch - Week 26 | 7.25 ± 1.73 | 8.49 ± 2.28 |
| Before dinner - Week 26: | 6.43 ± 1.61 | 6.77 ± 2.03 |
| Ninety (90) minutes after dinner - Week 26 | 7.85 ± 1.95 | 8.70 ± 2.19 |
| At bedtime - Week 26 | 7.05 ± 1.91 | 7.79 ± 2.20 |
| At 4.00 AM - Week 26 | 5.58 ± 1.17 | 5.72 ± 1.51 |
| Before breakfast the following day - Week 26 | 5.23 ± 1.09 | 5.36 ± 1.38 |
Change in mean of the 9-point profile SMPG was evaluated after 26 weeks of randomised treatment. 9-point profile SMPG was measured at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| Mean 9-point SMPG (mmol/L) at baseline | 9.98 ± 2.17 | 10.06 ± 2.04 |
| Mean 9-point SMPG change from baseline to week 26 | -3.47 ± 2.01 | -2.98 ± 1.91 |
Mean prandial plasma glucose increments for each meal (from before meal to 90 min after breakfast, lunch and dinner) was evaluated after 26 weeks of randomised treatment. The mean increment over all meals was derived as the mean of all available meal increments are presented here.
| mmol/L | IDegLira | IGlar |
|---|---|---|
| Baseline | 2.38 ± 1.73 | 2.28 ± 1.88 |
| Change from baseline to week 26 | -0.86 ± 1.95 | -0.09 ± 1.96 |
Change from baseline (week 0) in systolic blood pressure (BP) was evaluated after 26 weeks of randomised treatment.
| mmHg | IDegLira | IGlar |
|---|---|---|
| Systolic BP (mmHg) at baseline | 130.5 ± 14.3 | 128.9 ± 13.1 |
| Systolic BP (mmHg) change from baseline to week 26 | -3.0 ± 12.7 | 0.6 ± 12.0 |
Change from baseline (week 0) in diastolic blood pressure was evaluated after 26 weeks of randomised treatment.
| mmHg | IDegLira | IGlar |
|---|---|---|
| Diastolic (mmHg) at baseline | 79.4 ± 8.0 | 78.9 ± 8.9 |
| Diastolic (mmHg) change from baseline to week 26 | -1.2 ± 8.4 | -1.1 ± 8.3 |
Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes (00:01-05:59 - inclusive) during 26 weeks of randomised treatment.
| Number of episodes | IDegLira | IGlar |
|---|---|---|
| Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks | 6 | 13 |
American Diabetes Association (ADA) classification of hypoglycaemic episodes: 1)Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2) Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3) Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4) Probable symptomatic: No measurement with symptoms. 5) Pseudo: PG \>3.9 mmol/L with symptoms. 6) Unclassifiable.
| Number of episodes | IDegLira | IGlar |
|---|---|---|
| Severe - ADA | 1 | 0 |
| Documented symptomatic - ADA | 239 | 419 |
| Asymptomatic - ADA | 850 | 902 |
| Probably symptomatic - ADA | 23 | 5 |
| Pseudo - ADA | 10 | 14 |
| Unclassifiable hypoglycaemia - ADA | 2 | 0 |
Reported results are ECG findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.
| Number of subjects | IDegLira | IGlar |
|---|---|---|
| Screening, Normal | 142 | 141 |
| Screening, Abnormal NCS | 66 | 69 |
| Screening, Abnormal CS | 1 | 0 |
| Screening, Missing | 0 | 0 |
| Week 26, Normal | 134 | 136 |
| Week 26, Abnormal NCS | 58 | 64 |
| Week 26, Abnormal CS | 2 | 0 |
| Week 26, Missing | 0 | 0 |
Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is \<= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). 4) Missing.
| Number of subjects | IDegLira | IGlar |
|---|---|---|
| Screening, Left eye (Normal) | 134 | 131 |
| Screening, Left eye (Abnormal -NCS) | 68 | 74 |
| Screening, Left eye (Abnormal-CS) | 7 | 4 |
| Screening, Left eye (Missing) | 0 | 0 |
| Week 26, Left eye (Normal) | 123 | 125 |
| Week 26, Left eye (Abnormal -NCS) | 66 | 68 |
| Week 26, Left eye (Abnormal-CS) | 2 | 4 |
| Week 26, Left eye (Missing) | 0 | 0 |
| Screening, Right eye (Normal) | 133 | 133 |
| Screening, Right eye (Abnormal-NCS) | 69 | 72 |
| Screening, Right eye (Abnormal- CS) | 7 | 4 |
| Screening, Right eye (Missing) | 0 | 0 |
| Week 26, Right eye (Normal) | 120 | 127 |
| Week 26, Right eye (Abnormal-NCS) | 69 | 66 |
| Week 26, Right eye (Abnormal- CS) | 2 | 4 |
| Week 26, Right eye (Missing) | 0 | 0 |
Change from baseline (week 0) in pulse rate was evaluated after 26 weeks of randomised treatment.
| Beats/minute | IDegLira | IGlar |
|---|---|---|
| Pulse (beats/min) at baseline | 76.1 ± 9.1 | 75.0 ± 9.5 |
| Pulse (beats/min) change from baseline to week 26 | 2.0 ± 8.4 | -0.4 ± 8.2 |
The Short Form (SF)-36v2™ patient reported outcomes (PRO) questionnaire was used to assess the subject's overall health related quality of life (HRQoL). PRO questionnaire (SF-36v2™) measured the HRQoL which contains 36 items covering 8 domains of physical and mental health status. The raw scale scores from the SF-36 were transformed to a 0-100 scale scores (where higher scores indicated a better health status) which is further converted to norm-based scores using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 2009 reference population . The total/overall (SF-36v2™) scores for physical and mental health from baseline to week 26 are presented here.
| Scores on a scale | IDegLira | IGlar |
|---|---|---|
| Overall physical - Baseline | 51.3 (22.0 to 61.6) | 51.5 (21.9 to 62.4) |
| Overall physical - Week 26 | 53.2 (22.9 to 64.0) | 54.6 (25.0 to 65.6) |
| Overall mental - Baseline | 53.3 (15.6 to 67.9) | 53.3 (19.7 to 68.8) |
| Overall mental - Week 26 | 54.4 (14.8 to 68.3) | 54.4 (31.0 to 67.3) |
The patient reported outcomes are calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D domain scores and the total scores are later transformed to a 0-100 scale for analysis. Summary scores from baseline and week 26 for total/overall scores are presented here.
| Scores on a scale | IDegLira | IGlar |
|---|---|---|
| TRIM-D scores at baseline | 75.9 (44.6 to 100.0) | 75.9 (38.4 to 100.0) |
| TRIM-D scores at week 26 | 84.4 (37.5 to 100.0) | 83.9 (44.6 to 100.0) |
Collected over Adverse events (AEs) were collected from first day (week 0) of exposure to randomised treatment of 26 weeks + 30 days follow-up visits after the last dose on trial product. All reported AEs are treatment emergent (i.e., TEAE).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegLira | 0/209 (0%) | 6/209 (2.9%) | 49/209 (23.4%) |
| IGlar | 0/210 (0%) | 7/210 (3.3%) | 45/210 (21.4%) |
| Event | IDegLira | IGlar |
|---|---|---|
| PneumoniaInfections and infestations | 2/209 | 1/210 |
| Blood potassium increasedInvestigations | 1/209 | 0/210 |
| Cardiovascular evaluationInvestigations | 1/209 | 0/210 |
| Device failureProduct Issues | 1/209 | 0/210 |
| Haemorrhagic strokeNervous system disorders | 1/209 | 0/210 |
| Myocardial infarctionCardiac disorders | 1/209 | 0/210 |
| Abdominal painGastrointestinal disorders | 0/209 | 1/210 |
| Acute kidney injuryRenal and urinary disorders | 0/209 | 1/210 |
| Cardiac failure chronicCardiac disorders | 0/209 | 1/210 |
| Chronic kidney diseaseRenal and urinary disorders | 0/209 | 1/210 |
| Event | IDegLira | IGlar |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 16/209 | 22/210 |
| HeadacheNervous system disorders | 18/209 | 19/210 |
| Lipase increasedInvestigations | 12/209 | 3/210 |
| NauseaGastrointestinal disorders | 12/209 | 1/210 |
| Back painMusculoskeletal and connective tissue disorders | 11/209 | 9/210 |
The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intent-to-treat (ITT) principle and subjects contributed to the evaluation "as randomised".
| Age, Continuous(years) | IDegLira | IGlar | Total |
|---|---|---|---|
| Mean | 56.1 ± 10.4 | 57.2 ± 10.2 | 56.7 ± 10.3 |
| Sex: Female, Male(Participants) | IDegLira | IGlar | Total |
|---|---|---|---|
| Female | 89 | 84 | 173 |
| Male | 121 | 126 | 247 |
| Ethnicity (NIH/OMB)(Participants) | IDegLira | IGlar | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 37 | 68 |
| Not Hispanic or Latino | 179 | 173 | 352 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | IDegLira | IGlar | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 31 | 35 | 66 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 175 | 171 | 346 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Sep 2017, 16 months.
Results were first posted in Oct 2018, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide